Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: Implications for therapy

International Journal of Oncology

Volumn 12, Issue 3, 1998, Pages 665-669

  Fueyo, J ^a   Gomez Manzano, C ^a   Puduvalli, V K ^a   Martin Duque, P ^a   Perez Soler, R ^a   Levin, V A ^a   Yung, W K A ^a   Kyritsis, A P ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Glioma; p16; Paclitaxel; Topotecan; Tumor suppressor genes

Indexed keywords

CYTOTOXIC AGENT; PACLITAXEL; PROTEIN P16; TOPOTECAN;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL CYCLE G1 PHASE; CELL DEATH; CELL HETEROGENEITY; CHEMOSENSITIVITY; CONTROLLED STUDY; GLIOMA CELL; HUMAN; HUMAN CELL; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT;

EID: 0031883487     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.3.665     Document Type: Article

References (31)

1. Kyritsis AP: Evaluation and treatment of central nervous system neoplasms. In: Neurology Practice Guidelines. Lechtenberg R and Schutta HS (eds.) Marcel Dekker, New York, pp473-496, 1997.
2. Sidransky D, Mikkelsen T, Schwechheimer K, Rosemblum ML, Cavanee WK and Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846-887, 1992.
3. Henson JW; Schnitker BL, Correa KM, von Deimling A, Fassbender F, Xu H-J, Benedict WF, Yandell DW and Louis DN: The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 36: 714-721, 1994.
4. Venter DJ, Bevan KL, Ludwig RL, Riley TEW, Jat PS, Thomas DGT and Noble MD: Retinoblastoma gene deletions in human glioblastomas. Oncogene 6: 445-448, 1991.
5. Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WKA and Kyritsis AP: Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13: 1615-1619, 1996.
6. Ueki K, Ono Y, Henson JW, Efird JT, Von Deimling A and Louis DN: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153, 1996.
7. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.
8. Jen J, Harper W, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Wilson JKV, Kinzler W and Volgestein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358, 1994.
9. Schmidt EE, Ichimura K, Reifenberger G and Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994.
10. Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, Cunningham JE, Levin VA and Bruner J: Mutations of the p16 gene in gliomas. Oncogene 12: 63-67, 1996.
11. Costello JF, Berger MS, Huang H-J S and Cavanee WK: Silencing of p16/CDKN2 expression in human gliomas by methylation and cromatin condensation. Cancer Res 56: 2405-2410, 1996.
12. Fueyo J, Gomez-Manzano C, Yung WKA, Clayman GL, Liu TJ, Bruner J, Levin VA and Kyritsis AP: Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12: 103-110, 1996.
13. Arap W, Nishikawa IR, Furnari FB, Cavanee WK and Huang H-JS: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55: 1351-1354, 1995.
14. Wang J and Walsh K: Resistance to apoptosis conferred by cdk inhibitors during myocyte differentiation. Science 273: 359-361, 1996.
15. Stone S, Dayananth P and Kamb A: Reversible p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res 56: 3199-3202, 1996.
16. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA and Yung WKA: Adenovirus-mediated transfer of p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56: 694-699, 1996.
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
18. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA and Lassota P: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808, 1992.
19. Alaui SE, Lawry J and Griffin M: The cell cycle and induction of apoptosis in a hamster fibrosarcoma cell line treated with anticancer drugs: its importance to solid tumor chemotherapy. J Neurooncol 31: 195-207, 1997.
20. Kerr JFR, Winterford CM and Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013-2026, 1994.
21. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11: 121-139, 1992.
22. Searle J, Lawson TA, Abbott PJ, Harmon B and Kerr JFR: An electron-microscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol 116: 129-138, 1975.
23. INK4 expression in primary lung cancers and cell lines. Cancer Res 55: 505-509, 1995.
24. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O and Reznikoff C: Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 55: 493-497,1995.
25. Hass-Kogan DA, Kogan SC, Levi D, Dazin P, T'Ang A, Fung Y-KT and Israel MA: Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 14: 461-472, 1995.
26. Haupt Y, Rowan S and Oren M: p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 10: 1563-1571, 1995.
27. Poluha W, Poluha DK, Chang B, Crosbie NE, Schonhoff CM, Kilpatrick DL and Ross AH: The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol 16: 1335-1341, 1996.
28. Pandey S and Wang E: Cells en route to apoptosis are characterized by the upregulation of c-fos, c-myc, c-jun, cdc2 and RB phosphorylation, resembling events of early cell-cycle traverse. J Cell Biochem 58: 135-150, 1995.
29. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA and Yung WKA: Characterization of p53 and p21. functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 89: 1036-1044, 1997.
30. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL and Wilson CB: Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCO 6G61 final report. Int J Radiat Oncol Biol Phys 18: 321-324, 1990.
31. Kyritsis AP: Chemotherapy for malignant gliomas. Oncology 7: 93-100, 1993.